Table 1

Demographics and clinical features of study patients

Biopsies, n59
Subsequent enucleations of same eye, n21
Main reasons for enucleation, n
 Unfavourable tumour location11
 Tumour size too large for brachytherapy4
 Extrascleral extension2
 Extensive retinal detachment2
 Dense vitreous bleeding1
 Low potential for meaningful vision1
Mean age at biopsy, years (SD)61 (17)
Sex, n (%)
 Female27 (46)
 Male32 (54)
Median symptom duration before biopsy, years (IQR)0.5 (1.9)
Presentation, n (%)*
 Shadow in visual field19 (32)
 Visual impairment5 (9)
 Pain4 (7)
 Floaters3 (5)
No of incidental* tumour findings (%)28 (48)
Mean visual acuity at biopsy20/50
Mean tumour thickness at biopsy, mm (SD, min–max)3.8 (2.1, 1.0–10.5)
Mean tumour diameter at biopsy, mm (SD, min–max)9.3 (4.8, 2.0–25.0)
AJCC T-categoryAt biopsy, n (%)†At enucleation n (%)†
 137 (63)11 (52)
 214 (24)4 (19)
 34 (7)3 (14)
 44 (7)3 (14)
Median days from biopsy to enucleation (IQR, min–max)42 (23, 13–2512)
Median follow-up years (IQR, minimum-maximum)5.3 (5.1, 0.4–14.2)
Metastasis (%)
 Yes17 (29)
 No42 (71)
Melanoma-related death, n (%)
 Yes12 (20)
 No1 (2)
 Alive46 (78)
Biopsy BAP-1 classification, n (%)‡
 High37 (63)
 Low22 (37)
Enucleation BAP-1 classification, n (%)‡
 High13 (62)
 Low8 (38)
  • *Incidental tumour findings refers to tumours that were discovered upon fundus examination for other reasons, for example, screening for diabetic retinopathy, an optometrist’s examination or during preparations for cataract surgery.

  • †Percentage does not total 100 due to rounding.

  • ‡17 of 59 biopsies and 4 of 21 enucleations had complete absence of nuclear staining (0% positive tumour nuclei).

  • AJCC, American Joint Committee on Cancer; BAP-1, BRCA1-associated protein-1.